BioSpectrum India Magazine November issue BioSpectrum India Magazine | Page 28

28
COVERStory
BioSpectrum
|
November 2017
|
www.biospectrumindia.com
investors are thinking twice or thrice before investing in
this area, as it has more incubation time,” said Dr Shama
Bhat by adding that new areas of potential growth are
Molecular Diagnostics, Microarray based tests, New
Generation Sequencing (NGS), Hybridization and
FISH, PCR, POC, Pharmaco-genomics, and Smart-
phone based diagnostic products.
On sharing his views on newer technologies Pavan
Choudary, Director General, Medical Technology
Association India said, “The medical technology is
a wide spectrum ranging from
syringes to cyclotrons; from
urine bags to highly developed
ultrasonics. As we are moving
towards the spectrum, the
technology is becoming more and
more intricate. So in the simpler
side of the spectrum, right now we
have greater scope in the global
market. As you move towards
MAJOR PLAYERS IN INDIAN MARKET
 Hindustan Syringes & Medical Devices
 Opto Circuits (India)
 Wipro GE Healthcare
 3M
 Medtronic
 Johnson & Johnson
 Becton Dickinson
 Abbott Vascular
 Bausch & Lomb
 Baxter
 Zimmer India
 Edwards Life Sciences
 St. Jude Medical (now a part of Abbott)
 Stryker
 Baxter
 Boston Scientific
 BPL Healthcare India
 Sushrut Surgicals
 Trivitron Diagnostics
 Accurex Biomedical
